Compare Cytokinetics Inc (CYTK) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Krispy Kreme Inc — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Krispy Kreme Inc trades at $3.36 (market cap $574.09M). The key difference: Cytokinetics Inc is far larger — about 19.4× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | DNUT | |
|---|---|---|
Market Cap | $11.12B | $574.09M |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $4.70 |
52-Week Low | $33.23 | $2.92 |
Enterprise Value | $11.59B | $1.77B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Krispy Kreme (DNUT) trades at $3.47, up 0.87% today, with a bearish technical signal and mixed earnings history. The company reported a net loss of $515.77M in 2025 despite a gross margin of 75.56%, while analyst consensus leans bullish with 50% buy ratings. Recent news highlights strategic pivots to capital-light models and seasonal product launches to drive engagement.
Outlook remains challenged by persistent losses and high debt, but positive free cash flow in Q1 2026 and international growth potential offer catalysts. Key risks include execution on turnaround plans and competitive pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
